A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: Results after 18 months of therapy

Multiple Sclerosis

Volumn 7, Issue 6, 2001, Pages 349-353

  Khan, O A ^a   Tselis, A C ^a   Kamholz, J A ^a   Garbern, J Y ^a   Lewis, R A ^a   Lisak, R P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Glatiramer acetate; Interferon beta; Multiple sclerosis; Relapse rate

Indexed keywords

BETA1A INTERFERON; CPAXONE; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ANAMNESIS; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTIPLE SCLEROSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; STATISTICAL ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS;

EID: 0035211356     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245801701567041     Document Type: Article

References (17)

1. A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis
2. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
3. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
4. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
5. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
6. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double-blind, placebo-controlled trial
7. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability
8. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study
9. Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council Investigation
10. A comparison of observational studies and randomized controlled trials
11. Randomized, controlled trials, observational studies, and the hierarchy of research designs
12. Randomized trials or observational tribulations?
13. Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations
14. Randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis
15. A pilot trial of copolymer-1 in exacerbating-remitting multiple sclerosis
16. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis